Macrae Sandy 4

What Happened
Sandy Macrae, President, CEO and a director of Sangamo Therapeutics (SGMO), was granted a derivative equity award covering 2,500,000 shares on 2026-04-01. The reported price is $0.00, so no cash was paid; this is an equity award (grant) reported as a derivative transaction rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-01; Form 4 filed: 2026-04-03 (timely filing).
• Transaction type: Grant / award of derivative securities (code A).
• Amount: 2,500,000 shares; reported price $0.00 (no cash paid).
• Vesting: One-quarter (1/4) vests on the first anniversary of the grant, then the remainder vests in 24 equal monthly installments thereafter (total ~3 years), subject to continuous service and possible acceleration per the 2018 EIP.
• Shares owned after the grant: not specified in the provided filing details.
• No indication this was a sale or open-market purchase—this is compensation-related.

Context
This award appears to be a typical executive equity grant intended as compensation/retention (vesting over time). Such grants do not represent an immediate cash value until vested/exercised (if exercisable) or converted to shares, and they should not be interpreted the same way as an outright purchase or sale.